ENvue Medical Reports 51.6% Revenue Decline in Q2 2026 Amid Production Halt

ENvue Medical, Inc. reported a significant decline in financial performance for the second quarter of 2026, with revenues of $239,000, down 51.6% from $494,000 in the same period of 2025. For the first half of 2026, total revenues were approximately $892,000, a decrease of 41.3% compared to $1.519 million in the prior year. The company attributed this decline primarily to a halt in production of its PainShield/UroShield products due to the ongoing conflict in Israel and the subsequent relocation of manufacturing operations to the United States. Despite these challenges, ENvue's revenues from its ENvue systems increased by 275% during the quarter, reflecting growth in its installed hospital base and the adoption of its ENvue Navigation Platform.

The company's gross loss for the second quarter of 2026 was approximately $266,000, compared to a gross loss of $35,000 in the same quarter of 2025. This increase in gross loss was largely due to $140,000 in amortization of intangible assets related to the ENvue Merger, discounted sales of ENvue systems, and inventory write-downs totaling $41,000. Operating expenses also rose significantly, with total operating expenses reaching $5.208 million for the quarter, up from $3.941 million in the prior year, driven by increased selling and marketing efforts and general administrative costs.

ENvue Medical's net loss for the second quarter of 2026 was approximately $4.899 million, an increase of 23% from a net loss of $3.971 million in the same period of 2025. The company reported a basic and diluted net loss per common share of $1.98 for the quarter, compared to $1.03 in the previous year. The increase in net loss was attributed to higher operating expenses and the factors affecting revenue generation.

In terms of operational developments, ENvue Medical has been focusing on expanding its market presence and product adoption. The company has seen a notable increase in its customer base, particularly in the ENvue segment, which has benefited from new purchasing agreements with group purchasing organizations representing over 100 U.S. hospitals. The company also reported a significant increase in its employee headcount as it continues to build its sales and marketing teams to support its growth initiatives.

Looking ahead, ENvue Medical faces challenges related to its liquidity, with cash and cash equivalents decreasing to $1.084 million as of June 30, 2026, down from $4.030 million a year earlier. The company has indicated that it will need to raise additional capital to fund its operations and continue its growth trajectory. ENvue Medical has entered into a Common Shares Purchase Agreement with Alpha Capital Anstalt, allowing it to sell up to $50 million of its common stock, which it plans to use for working capital and to redeem outstanding shares of its Series X Preferred Stock. The company remains optimistic about resuming production and achieving profitability, although it acknowledges the uncertainties posed by geopolitical conditions and market dynamics.